hetrombopag

Phase 3Small molecule

JJiangsu HengRui Medicine Co., Ltd.

hetrombopag is one of 99 small molecule programs targeting Thrombocytopenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombocytopeniaRecruiting

NeuroblastomaActive, not recruiting

Allogeneic Hematopoietic Stem Cell TransplantationUnknown status

ThrombocytopeniaPhase 3

Recruiting

NeuroblastomaPreclinical

Active, not recruiting

Allogeneic Hematopoietic Stem Cell TransplantationPreclinical

Unknown status

Competition

Competitive Landscape

83 competitors in Neuroblastoma

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

53 2

Vepesid

AAvyxa

Phase 3

40 3

Paraplatin

AAvyxa

Phase 3

35 4

Leukine

Sanofi

Phase 3

15 5

Camptosar

Pfizer

Phase 3

12 6

Tepadina

Jazz Pharmaceuticals

Phase 3

11 7

Alkeran

AApotex Inc.

Phase 3

28 8

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

26 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Adriamycin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Thrombocytopenia

NCT07408648

Phase 2Not yet recruiting

Thrombocytopenia

NCT07101627

Q3 2027

N/ARecruiting

Neuroblastoma

NCT06818916

Q4 2027

Phase 2Not yet recruiting

Thrombocytopenia

NCT07334093

Clinical

Trials by Indication[1]

Thrombocytopenia15 trials

Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.

Unknown status·TTongji Hospital·Phase 2·NCT05392647·28 enrolled

Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia

Recruiting·—·Phase 4·NCT06562738·55 enrolled

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer

Recruiting·HHenan Cancer Hospital·Phase 2·NCT05394285·60 enrolled

Show 12 more trials

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03976882·129 enrolled

Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

Recruiting·FFudan University·Phase 2·NCT05442632·96 enrolled

A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients.

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07334093·204 enrolled

The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06099925·48 enrolled

A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07408648·244 enrolled

A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT07101627·149 enrolled

Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia

Unknown status·PPeking Union Medical College Hospital·Phase 2/3·NCT05024877·50 enrolled

The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06036966·34 enrolled

Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors

Recruiting·—·Phase 2·NCT07492693·40 enrolled

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT05864014·213 enrolled

Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma

Unknown status·SSun Yat-sen University·Phase 2·NCT05969158·90 enrolled

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Withdrawn·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT05261646

Severe Aplastic Anemia1 trial

Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia

Unknown status·PPeking Union Medical College Hospital·Phase 2/3·NCT05018936·40 enrolled

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04688008·58 enrolled

4 more indications

Statin1 trial

Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT05088343·14 enrolled

Neuroblastoma1 trial

Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma

Recruiting·—·N/A·NCT06818916·30 enrolled

Immune Thrombocytopenia1 trial

Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04737850·100 enrolled

Thalassemia in Children1 trial

An Observational Study on the Promotion of Platelet Recovery by Hetrombopag During Haploidentical Hematopoietic Stem Cell Transplantation

Completed·HHaikou Affiliated Hospital of Central South University Xiangya School of Medicine··NCT07003269·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for hetrombopag. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hetrombopag compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hetrombopag. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

hetrombopag

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Thrombocytopenia15 trials

Severe Aplastic Anemia1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Effectiveness1 trial

LAM1 trial

Statin1 trial

Neuroblastoma1 trial

Immune Thrombocytopenia1 trial

Thalassemia in Children1 trial

References

Drug Info

Quick Facts

Related News